Related Experiment Video
Updated: May 28, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
[Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability]
1Université de Toulouse, institut Claudius-Regaud, France. Chatelut.Etienne@claudiusregaud.fr
Abstract:
Platinum compounds represent a pharmacological class, essential for the treatment of some cancer diseases. The three molecules, cisplatin, carboplatin, and oxaliplatin, share some physiochemical and pharmacological properties, in particular the ability to form DNA adducts. However, oxaliplatin presents some mechanisms of resistance different to those of cisplatin and carboplatin. Carboplatin may be considered as an analogue of cisplatin, but its pharmacokinetic properties, side effects, and intrinsic activity are significantly different from those of cisplatin, then the choice of one of these two compounds may be done rationally in function of the patients' characteristics. The cellular mechanisms involved in these differences are described in this general review.
Related Concept Videos
Dosage Regimen: Individualization
Drug toxicity: Idiosyncratic Reactions
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Principles of Pharmacogenetics: Types of Genetic Variants
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...

